Effectiveness versus convenience: patient preferences for an erythropoietic agent to treat cancer-related anemia

References

• Pujade-Lauraine E, Gascón P. The burden of anaemia in patients with cancer. Oncology 2004;67(Suppl 1):1–4
   PubMedGoogle Scholar
• Cella D, Dobrez D, Glaspy J. Control of cancer-related anemia with erythropoietic agents: A review of evidence for improved quality of life and clinical outcomes. Ann Oncol 2003;14:511–9
   Google Scholar
• Morère JF. Role of epoetin in the management of anaemia in patients with lung cancer. Lung Cancer 2004;46:149–56
   PubMed Web of Science ®Google Scholar
• Stone P, Richards M, A’Hern R, et al. A study to investigate the prevalence, severity and correlates of fatigue among patients with cancer in comparison with a control group of volunteers without cancer. Ann Oncol 2000;11:561–7
   Google Scholar
• Gillespie TW. Effects of cancer-related anemia on clinical and quality-of-life outcomes. Clin J Oncol Nurs 2002;6:1–6
   Google Scholar
• Witzig TE, Silberstein PE, Loprinzi CL, et al. Phase II, randomized, double-blind study of epoetin alfa versus placebo in anemic patients with cancer undergoing chemotherapy. J Clin Oncol 2005;23:2606–17
   PubMed Web of Science ®Google Scholar
• Shasha D, George MJ, Harrison LB. Once weekly dosing of epoetin-alpha increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy. Cancer 2003;98:1072–9
   Google Scholar
• Cella D, Zagari MJ, Vandoros C, et al. Epoetin alfa treatment results in clinically significant improvements in quality of life in anemic cancer patients when referenced to the general population. J Clin Oncol 2003;21:366–73
   PubMed Web of Science ®Google Scholar
• Gabrilove JL, Cleeland CS, Livingston RB, et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001;19:2875–82
   PubMed Web of Science ®Google Scholar
• Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999;1:1616–34
   Google Scholar
• Demetri GD, Kris M, Wade J, et al. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. J Clin Oncol 1998;16:3412–25
   PubMed Web of Science ®Google Scholar
• Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer 2001;84(Suppl 1):3–10
   PubMed Web of Science ®Google Scholar
• Macdougall IC. Optimizing the use or erythropoietic agents – pharmacokinetic and pharmacodynamic considerations. Nephrol Dial Transplant 2002;17(Suppl 5):66–70
   PubMed Web of Science ®Google Scholar
• Valley AW. Overview of cancer-related anemia: focus on the potential role of darbepoetin alfa. Pharmacotherapy 2002;22\(Suppl 2):150–9S
   Google Scholar
• Ryan M, Scott DA, Reeves C, et al: Eliciting public preferences for healthcare: a systematic review of techniques. Health Technol Assess 2001;5:1–186
   PubMedGoogle Scholar
• Sawtooth Software, Inc. Choice-based conjoint (CBC) technical paper. Sequim, WA, 2001
   Google Scholar
• Stewart M, Brown JB, Donner A. The impact of patient-centered care on patient outcomes. J Fam Pract 2000;49:796–804
   Google Scholar
• Garrity TF. Medical compliance and the clinician-patient relationship. Soc Sci Med 1981;15:215–22
   Web of Science ®Google Scholar
• Krupat E, Bel RA, Kravitz RL, et al. When physicians and patients think alike: patient-centered beliefs and their impact on satisfaction and trust. J Fam Pract 2001;50:1057–62
   PubMed Web of Science ®Google Scholar
• Bokemeyer C, Foubert J. Anemia impact and management: focus on patient needs and the use of erythropoietic agents. Semin Oncol 2004;31(Suppl 8):4–11
   PubMedGoogle Scholar
• Osoba D, Hsu M, Copley-Merriman C, et al. Stated preferences of patients with cancer for health-related quality-of-life (HRQOL) domains during treatment. Qual Life Res 2006;15:273–83
   Google Scholar
• Johnson FR, Hauber AB, Osoba D, et al. Are chemotherapy patients’ HRQoL importance weights consistent with linear scoring rules? A stated-choice approach. Qual Life Res 2006; 15:285–98
   PubMed Web of Science ®Google Scholar
• Rosberg J, Lefebvre P, Fastenau J, et al. Clinical significance of a ≥ 1g/dL rise in hemoglobin at week 4 or at week 8 during epoetin alfa treatment (abstr). Blood 2003;102:510b
   Google Scholar
• Sawtooth Software, Inc. Adaptive conjoint analysis (ACA) technical paper. Sequim, WA, 2002
   Google Scholar
• Orme B. Which conjoint method should I use? Sawtooth Software, Inc. Research Paper Series. Sequim, WA, 2003
   Google Scholar
• Best SJ, Krueger B, Hubbard C, et al. An assessment of the generalizability of internet surveys. Soc Sci Comput Rev 2001;19:131–45
   Web of Science ®Google Scholar
• Gillespie K, Andresen E, Boslaugh, S, Recktenwalk A. (In)consistency of preference ratings: results using three methods of preference elicitation. Inaugural American Society of Health Economists Conference, Madison, Wisconsin, June 4–8, 2006
   Google Scholar
• Allan L, Hays H, Jensen N, et al. Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain. Br Med J 2001;322:1154–8
   PubMed Web of Science ®Google Scholar
• Weinberg EG, Naya I. Treatment preferences of adolescent patients with asthma. Pediatr Allergy Immunol 2000;11:49–55
   PubMed Web of Science ®Google Scholar
• Johnson M, Guilford S, Libretto SE. Patients have treatment preferences: a multicentre, double-blind, crossover study comparing rabeprazole and omeprazole. Curr Med Res Opin 2002;18:303–10
   Google Scholar
• Shikiar R, Rentz AM. Satisfaction with medication: an overview of conceptual, methodological, and regulatory issues. Value Health 2004;7:204–15
   PubMed Web of Science ®Google Scholar